Literature DB >> 354980

Pituitary gonadotropin inhibition by a highly active analog of luteinizing hormone-releasing hormone.

J Sandow, W Von Rechenberg, G Jerzabek, W Stoll.   

Abstract

Chronic treatment with highly active analogs of luteinizing hormone (LH)-releasing hormone (LH-RH) induces "paradoxical" antifertility effects. Intact male rats, a reduction in testosterone production is observed after the administration of [D-Ser(But)6]-LH-RH(1-9)ethylamide (burserelin, Hoe 766), 50 ng/day subcutaneously for 4 weeks. In castrated male rats treated with the same dose of analog, plasma LH levels were reduced from days 14 to 28 and plasma follicle-stimulating hormone (FSH) levels were reduced from days 21 to 28 of treatment. Pituitary LH and FSH concentrations were also decreased. The plasma prolactin level was reduced at 14 days of treatment. The hypothalamic LH-RH content remained unchanged and the adrenal corticosterone content was lowered. These findings indicate a direct inhibitory effect of the analog on gonadotropin secretion in the absence of the gonads, and may explain some paradoxical antifertility effects observed with high doses of LH-RH analogs which exceed the physiologic dose range.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 354980     DOI: 10.1016/s0015-0282(16)43461-8

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  23 in total

Review 1.  A history of prostate cancer treatment.

Authors:  Samuel R Denmeade; John T Isaacs
Journal:  Nat Rev Cancer       Date:  2002-05       Impact factor: 60.716

Review 2.  Current concepts in the treatment of genitourinary tract disorders in the older individual.

Authors:  A Atala; M Amin
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

Review 3.  CYP17A1 inhibitors in castration-resistant prostate cancer.

Authors:  Lissette Gomez; Jason R Kovac; Dolores J Lamb
Journal:  Steroids       Date:  2015-01-03       Impact factor: 2.668

4.  Radioimmunoassay for 6-D-tryptophan analog of luteinizing hormone-releasing hormone: measurement of serum levels after administration of long-acting microcapsule formulations.

Authors:  M Mason-Garcia; S Vigh; A M Comaru-Schally; T W Redding; A Somogyvari-Vigh; J Horvath; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

5.  Sensitivity of luteinizing hormone and gonadal steroid responses to single intranasal administration of an LHRH agonist (Hoe-766) in young normal adult men.

Authors:  N Faure; F Labrie; A Belanger; A Lemay; J P Raynaud; M Von der Ohe; A T Fazekas
Journal:  J Endocrinol Invest       Date:  1982 Nov-Dec       Impact factor: 4.256

6.  Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments.

Authors:  J G Klijn
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

7.  Adaptation of the pituitary gland to prolonged LRH stimulation.

Authors:  T R Koiter; N Pols-Valkhof; G A Schuiling
Journal:  Experientia       Date:  1981-12-15

8.  Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer.

Authors:  J G Klijn; F H de Jong; M A Blankenstein; R Docter; J Alexieva-Figusch; J Blonk-van der Wijst; S W Lamberts
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

9.  Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.

Authors:  G Tolis; D Ackman; A Stellos; A Mehta; F Labrie; A T Fazekas; A M Comaru-Schally; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

10.  Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules.

Authors:  T W Redding; A V Schally; T R Tice; W E Meyers
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.